-
EP3630125
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3630125
| EP3630125 - SENOLYTIC COMPOUNDS [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 23.06.2023 Database last updated on 03.09.2024 | |
| Former | Examination is in progress Status updated on 14.05.2021 | ||
| Former | Request for examination was made Status updated on 06.03.2020 | ||
| Former | The international publication has been made Status updated on 01.12.2018 | ||
| Former | unknown Status updated on 23.06.2018 | Most recent event Tooltip | 23.06.2023 | Application deemed to be withdrawn | published on 26.07.2023 [2023/30] | Applicant(s) | For all designated states United Kingdom Research and Innovation Polaris House North Star Avenue Swindon SN2 1FL / GB | [2020/15] | Inventor(s) | 01 /
GIL, Jesus MRC London Institute of Medical Sciences Hammersmith Hospital Campus Du Cane Road London W12 0NN / GB | 02 /
GUERRERO, Ana MRC London Institute of Medical Sciences Hammersmith Hospital Campus Du Cane Road London W12 0NN / GB | 03 /
HARRANZ, Nicolas MRC London Institute of Medical Sciences Hammersmith Hospital Campus Du Cane Road London W12 0NN / GB | [2020/15] | Representative(s) | D Young & Co LLP 3 Noble Street London EC2V 7BQ / GB | [N/P] |
| Former [2020/15] | D Young & Co LLP 120 Holborn London EC1N 2DY / GB | Application number, filing date | 18730422.5 | 25.05.2018 | [2020/15] | WO2018GB51437 | Priority number, date | GB20170008456 | 26.05.2017 Original published format: GB 201708456 | [2020/15] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2018215795 | Date: | 29.11.2018 | Language: | EN | [2018/48] | Type: | A2 Application without search report | No.: | EP3630125 | Date: | 08.04.2020 | Language: | EN | The application published by WIPO in one of the EPO official languages on 29.11.2018 takes the place of the publication of the European patent application. | [2020/15] | Search report(s) | International search report - published on: | EP | 03.01.2019 | Classification | IPC: | A61K31/704, A61K31/585, A61P43/00 | [2020/15] | CPC: |
A61K31/704 (EP,US);
A61K31/137 (US);
A61K31/03 (US);
A61K31/122 (US);
A61K31/18 (US);
A61K31/34 (US);
A61K31/352 (US);
A61K31/426 (US);
A61K31/4709 (US);
A61K31/4745 (US);
A61K31/475 (US);
A61K31/585 (EP);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/15] | Title | German: | SENOLYTISCHE VERBINDUNGEN | [2020/15] | English: | SENOLYTIC COMPOUNDS | [2020/15] | French: | COMPOSÉS SÉNOLYTIQUES | [2020/15] | Entry into regional phase | 12.12.2019 | National basic fee paid | 12.12.2019 | Designation fee(s) paid | 12.12.2019 | Examination fee paid | Examination procedure | 12.12.2019 | Examination requested [2020/15] | 12.12.2019 | Date on which the examining division has become responsible | 08.06.2020 | Amendment by applicant (claims and/or description) | 14.05.2021 | Despatch of a communication from the examining division (Time limit: M04) | 17.09.2021 | Reply to a communication from the examining division | 18.10.2022 | Despatch of a communication from the examining division (Time limit: M04) | 01.03.2023 | Application deemed to be withdrawn, date of legal effect [2023/30] | 22.03.2023 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2023/30] | Fees paid | Renewal fee | 19.03.2020 | Renewal fee patent year 03 | 14.05.2021 | Renewal fee patent year 04 | 20.05.2022 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [X]WO2015116735 (MAYO FOUNDATION [US]) [X] 1-4,10,23-25,28,29,32-34 * claims 1,5-9,14 * * examples 1-17 *; | [X]WO2015116740 (BUCK INST FOR RES ON AGING [US], et al) [X] 1-4,10,23-25,28,29,32-34 * claims 1,14-22,96-109 * * examples 1-32 *; | [X] - SCHMITT ROLAND ED - PETERSEN OLE ET AL, "Senotherapy: growing old and staying young?", PFLUEGERS ARCHIV: EUROPEAN JOURNAL OF PHYSIOLOGY, SPRINGER VERLAG, BERLIN, DE, vol. 469, no. 9, doi:10.1007/S00424-017-1972-4, ISSN 0031-6768, (20170407), pages 1051 - 1059, (20170407), XP036295313 [X] 1-4,10,23-25,28,29,32-34 * table 2 * DOI: http://dx.doi.org/10.1007/s00424-017-1972-4 | [X] - SAMARAWEERA LELEESHA ET AL, "A Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC", SCIENTIFIC REPORTS, (20170515), vol. 7, XP002783686 [X] 1-4,10,23-25,28,29,32-34 * page 1, abstract * | [X] - WANG YINGYING ET AL, "Discovery of piperlongumine as a potential novel lead for the development of senolytic agents", AGING-US, (201611), vol. 8, no. 11, ISSN 1945-4589, pages 2915 - 2926, XP002783687 [X] 1-4,10,23-25,28,29,32-34 * page 2915, abstract * DOI: http://dx.doi.org/10.18632/aging.101100 | [X] - ZHOU-JI ZHANG ET AL, "Bufalin attenuates the stage and metastatic potential of hepatocellular carcinoma in nude mice", JOURNAL OF TRANSLATIONAL MEDICINE, BIOMED CENTRAL, (20140228), vol. 12, no. 1, doi:10.1186/1479-5876-12-57, ISSN 1479-5876, page 57, XP021180945 [X] 1,2,4,10,23,28,29,32,34 * page 57, abstract * DOI: http://dx.doi.org/10.1186/1479-5876-12-57 | [X] - WU SHIN-HWAR ET AL, "Bufalin Induces Cell Death in Human Lung Cancer Cells through Disruption of DNA Damage Response Pathways", AMERICAN JOURNAL OF CHINESE MEDICINE, (2014), vol. 42, no. 3, pages 729 - 742, XP009507297 [X] 1,2,4,10,23,28,29,32,34 * page 729, abstract * DOI: http://dx.doi.org/10.1142/S0192415X14500475 |